Absence of Behavioral Abnormalities and Neurodegeneration in vivo despite Widespread Neuronal Huntingtin Inclusions

We have serendipitously established a mouse that expresses an N-terminal human huntingtin (htt) fragment with an expanded polyglutamine repeat (≈120) under the control of the endogenous human promoter (shortstop). Frequent and widespread htt inclusions occur early in shortstop mice. Despite these in...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 102; no. 32; pp. 11402 - 11407
Main Authors Slow, Elizabeth J., Graham, Rona K., Osmand, Alexander P., Devon, Rebecca S., Lu, Ge, Deng, Yu, Pearson, Jacqui, Vaid, Kuljeet, Bissada, Nagat, Wetzel, Ronald, Leavitt, Blair R., Hayden, Michael R., Palmiter, Richard D.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 09.08.2005
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We have serendipitously established a mouse that expresses an N-terminal human huntingtin (htt) fragment with an expanded polyglutamine repeat (≈120) under the control of the endogenous human promoter (shortstop). Frequent and widespread htt inclusions occur early in shortstop mice. Despite these inclusions, shortstop mice display no clinical evidence of neuronal dysfunction and no neuronal degeneration as determined by brain weight, striatal volume, and striatal neuronal count. These results indicate that htt inclusions are not pathogenic in vivo. In contrast, the full-length yeast artificial chromosome (YAC) 128 model with the identical polyglutamine length and same level of transgenic protein expression as the shortstop demonstrates significant neuronal dysfunction and loss. In contrast to the YAC128 mouse, which demonstrates enhanced susceptibility to excitotoxic death, the shortstop mouse is protected from excitotoxicity, providing in vivo evidence suggesting that neurodegeneration in Huntington disease is mediated by excitotoxic mechanisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
E.J.S. and R.K.G. contributed equally to this work.
This paper was submitted directly (Track II) to the PNAS office.
To whom correspondence should be addressed at: Centre for Molecular Medicine and Therapeutics, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4. E-mail: mrh@cmmt.ubc.ca.
Abbreviations: HD, Huntington disease; htt, huntingtin; polyQ, polyglutamine; AF, aggregation foci; YAC, yeast artificial chromosome; QA, quinolinic acid; NI, neuronal inclusion.
Edited by Richard D. Palmiter, University of Washington School of Medicine, Seattle, WA
Author contributions: E.J.S., R.K.G., A.P.O., R.S.D., and M.R.H. designed research; E.J.S., R.K.G., A.P.O., R.S.D., G.L., Y.D., J.P., K.V., and N.B. performed research; R.W. contributed new reagents/analytic tools; E.J.S., R.K.G., A.P.O., and R.S.D. analyzed data; and E.J.S. and M.R.H. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0503634102